NICE nod for Darzalex with lenalidomide and dexamethasone
Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma
Read More
Tag: lenalidomide
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read More
FDA approves Sarclisa for relapsed refractory multiple myeloma
The approval of the monoclonal antibody “provides a new treatment option for patients whose disease has returned or become resistant to their prior treatments.”
Read More
Empliciti combo bags EU approval for multiple myeloma
The approval is based on data from the ELOQUENT-3 trial.
Read More
NICE recommends Revlimid as multiple myeloma alternative
The new indication will benefit approximately 2,100 patients.
Read More
Rituximab found to extend progression-free survival in indolent lymphoma
New trial results have been published showing that a combination of Celgene’s Revlimid and Roche’s rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.
Read More
Revlimid boosts survival in myeloma patients post-transplant
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
Read More
FDA puts on hold Keytruda studies
US regulators have placed on clinical hold three studies testing the immunotherapy Keytruda in combination with other therapies for multiple myeloma because of patient deaths.
Read More
Merck pauses Keytruda studies to assess patient deaths
Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
Read More
Takeda’s Ninlaro rejected by NICE for multiple myeloma
Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its mutilple myeloma drug Ninlaro following an initial rejection by the cost watchdog.
Read More
EU expands use of Revlimid to include post ACST use
European regulators have expanded the scope of Celgene’s Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Read More
NICE rejects earlier use of multiple myeloma drugs
Patients with multiple myeloma are being barred from routine access on the NHS to Celgene’s Revlimid and Amgen’s Kyprolis in the second-line setting.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
